Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesLack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis
Neurological Sciences, 09/23/09
Centonze D et al. – Sativex failed to affect spasticity and stretch reflex excitability. This compound also failed to affect the synthesis and the degradation of the endocannabinoid anandamide, as well as the expression of both CB1 and CB2 cannabinoid receptors in various subpopulations of peripheral lymphocytes.
Related Articles
APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis
Multiple Sclerosis, 11/19/09
Relevance Score: 69%
Early Psychiatric Manifestation in a Patient with Primary Progressive Multiple Sclerosis
Archives of Iranian Medicine, 11/12/09
Relevance Score: 69%
Cochlear implantation in a profoundly deaf patient who also suffers from multiple sclerosis - a case study
Cochlear Implants International, 10/27/09
Relevance Score: 69%
A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
Multiple Sclerosis, 10/01/09
Relevance Score: 69%
Early Drug Treatment May Cut Multiple Sclerosis Risk
MedLinePlus, 10/08/09
Relevance Score: 68%
Today in Demyelinating Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Psychosocial dysfunction in the first year after Guillain-Barré syndrome
Muscle & Nerve, 12/02/09
Multiple sclerosis in the Faroe Islands. 8. Notifiable diseases
Acta Neurologica Scandinavica, 12/02/09
Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: A phase II open label clinical trial
Amyotrophic Lateral Sclerosis, 12/01/09
Sponsor
Article Search
Sponsor